By analyzing E. coli protein levels, scientists found a surplus of membrane shuttle proteins that may play a role in antibiotic resistance.
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
New study explores the use of Random Antimicrobial Peptide Mixtures (RPMs) as a safe and effective alternative to antibiotics in cultured meat ...
Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...
Hosted on MSN8d
The Antibiotic Arms Race: Can Science Stay Ahead of Rapidly Evolving Antibiotic-Resistant Bacteria?A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
GlobalData on MSN8d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback